Results of the methodological assessment by the European Lung Cancer Working Party score
| Studies n | Global score % | Design* | Laboratory methodology* | Genera-lizability* | Results analysis* | |
| All studies | 74 | 54.8 | 4.0 | 5.7 | 6.7 | 5.6 |
| Evaluated for the MA | 56 | 54.8 | 4.0 | 5.7 | 6.6 | 5.6 |
| Noevaluated for the MA | 18 | 54.6 | 4.5 | 5.7 | 6.6 | 5.0 |
| p-;value | 0.72 | 0.83 | 0.89 | 0.81 | 0.16 | |
| Positive | 30 | 55.1 | 4.4 | 6.4 | 6.6 | 6.2 |
| Negative | 44 | 54.3 | 4.0 | 5.7 | 6.6 | 3.7 |
| p-;value | 0.24 | 0.57 | 0.49 | 0.94 | 0.02 | |
| IHC | 35 | 56.5 | 4.0 | 6.4 | 6.6 | 6.2 |
| MB | 14 | 52.4 | 4.0 | 4.0 | 6.6 | 5.6 |
| p-;value | 0.07 | 0.31 | 0.0002 | 0.29 | 0.88 |
Score distributions are summarized by the median values
*: score out of 10
Positive: studies identifying p53 positivity as significant poor prognostic factor for survival
Negative: studies reporting nonsignificant results, or identifying p53 positivity as associated with better survival
IHC: immunohistochemistry
MB: molecular biology
MA: meta-analysis